Back to today’s briefing

Story perspectives

Tofersen Breakthrough: Promising ALS Treatment Reduces Mortality Risk

12/22/2025

34 5

Summary

Story summary

Tofersen shows promise in slowing progression of SOD1-ALS, a rare form affecting about 2% of ALS patients.
A recent study shows over 20% of participants gained strength and function after three years.
The spinal-injection treatment yields a 48% reduction in mortality risk for early users.
Jessica Morris reports meaningful quality-of-life improvements and some regained mobility.
Researchers say tofersen could advance treatment for other ALS forms.

1 of 1

Story summary

Tofersen shows promise in slowing progression of SOD1-ALS, a rare form affecting about 2% of ALS patients.
A recent study shows over 20% of participants gained strength and function after three years.
The spinal-injection treatment yields a 48% reduction in mortality risk for early users.
Jessica Morris reports meaningful quality-of-life improvements and some regained mobility.
Researchers say tofersen could advance treatment for other ALS forms.